glp-1 drugs companies 9 Developing Next-Generation High cost of GLP-1 drugs

Both the American Diabetes Association (ADA), in conjunction with the European Association for the Study of Diabetes (EASD), and KDIGO provide clinical practice guidelines for diabetes management in CKD [2, 3]

For instance, in November 2024, Novo Nordisk struck a USD 285 million deal with Ascendis Pharma in order to advance a once-monthly GLP-1 receptor agonist for obesity and diabetes treatment

However, individual reactions and side effects may vary

If an older adult with already diminishing muscle reserves undergoes rapid weight loss, they risk accelerating sarcopenia, leading to a condition known as sarcopenic obesity